title: The role of prophylactic antimicrobials during autologous stem cell transplantation: a single-center experience.
abstract: The aim of this study was to investigate the efficacy of antibiotic prophylaxis in patients undergoing autologous stem cell transplantation (ASCT) for multiple myeloma and non-Hodgkin lymphoma. Among 232 ASCT cases performed at the Asan Medical Center, 114 cases underwent treatment with ciprofloxacin, fluconazole, and acyclovir (between January 2001 and August 2005), while 118 cases were performed without antimicrobial prophylaxis (between February 2004 and June 2008). The two-rate χ2 test was applied to accommodate the differences in neutropenia duration. The incidence of febrile episodes was 9.8 cases per 100 person-days in the prophylactic group, while it was 16.2 cases in the no-prophylactic group (p<0.001). The rate of unexplained fever was 8.0 cases per 100 person-days in the prophylactic group, while it was 13.8 cases in the no-prophylactic group (p<0.001). The rate of clinically and microbiologically documented infection was 1.7 cases per 100 person-days in the prophylactic group, while it was 2.3 cases in the no-prophylactic group (p=0.404). There were fewer cases of methicillin-susceptible Staphylococcus aureus infection and a greater number of quinolone-resistant Escherichia coli in the prophylactic group compared with the no-prophylactic group (p=0.056 and p=0.040, respectively). The prophylactic antimicrobials reduced the incidence rate of febrile episodes, especially unexplained fever, despite there being no difference in the incidence of documented infection. Resistant microbe infection occurred more frequently in the prophylactic group.
authors.affiliation: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Sanggye Paik Hospital, 86 Asanbyeongwon-gil, Songpa-gu, Seoul, 138-736, Korea.
authors.forename: B S
authors.initials: BS
authors.lastname: Sohn
authors.forename: D H
authors.initials: DH
authors.lastname: Yoon
authors.forename: S
authors.initials: S
authors.lastname: Kim
authors.forename: K
authors.initials: K
authors.lastname: Lee
authors.forename: E H
authors.initials: EH
authors.lastname: Kang
authors.forename: J S
authors.initials: JS
authors.lastname: Park
authors.forename: D H
authors.initials: DH
authors.lastname: Lee
authors.forename: S H
authors.initials: SH
authors.lastname: Kim
authors.forename: J
authors.initials: J
authors.lastname: Huh
authors.forename: C
authors.initials: C
authors.lastname: Suh
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000935:Antifungal Agents / Q000008:administration & dosage; D000998:Antiviral Agents / Q000008:administration & dosage; D018890:Chemoprevention / Q000379:methods*; D002939:Ciprofloxacin / Q000008:administration & dosage*; D004926:Escherichia coli / Q000302:isolation & purification; D005260:Female; D005335:Fever of Unknown Origin / Q000453:epidemiology / Q000517:prevention & control*; D015725:Fluconazole / Q000008:administration & dosage*; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D008297:Male; D008875:Middle Aged; D013211:Staphylococcus aureus / Q000302:isolation & purification; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D000998:Antiviral Agents; D002939:Ciprofloxacin; D015725:Fluconazole; D000212:Acyclovir